Millipore Sigma Vibrant Logo

341600 Fibrinogen, Fragment D, Human Plasma

View This Product on Sigma-Aldrich
341600
価格&在庫状況を照会

概要

Replacement Information

価格&在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
341600-200UGCN
在庫状況検索中…
現在国内在庫なし
現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      樹脂アンプル 200 μg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示 
      値引
      ()
       
      弊社照会
      Description
      OverviewNative fibrinogen fragment D from human plasma prepared by plasmin digestion of purified fibrinogen followed by preparative electrophoresis. Thermolabile core fragment of fibrinogen. Complete proteolysis of a single fibrinogen molecule produces two D and one E fragments. The D and E fragments have no common antigenic determinants; therefore, no cross-reaction occurs. Reported to increase endothelial membrane permeability to albumin.
      Catalogue Number341600
      Brand Family Calbiochem®
      References
      ReferencesSpraggon, G., et al. 1997. Nature 389, 455.
      Stirk, C.M., et al. 1993. Atherosclerosis 103, 159.
      Vogel, P., et al. 1993. Eur. Surg. Res. 25, 83.
      Azpiazu, I., and Chapman, D. 1992. Biochim. Biophys. Acta 1119, 268.
      Thompson, W.D., et al. 1992. J. Pathol. 168, 47.
      Fisher, E.G., et al. 1991. Haemostasis 21, 141.
      Ge, M., et al. 1991. Am. J. Physiol. 261, L283.
      Product Information
      FormLyophilized
      FormulationLyophilized from 400 mM glycine, 150 mM NaCl.
      Quality LevelMQ200
      Applications
      ApplicationFibrinogen fragment D is a thermolabile native human plasma protein prepared by digestion of purified fibrinogen followed by preparative electrophoresis.
      Biological Information
      Puritysingle band by SDS-PAGE
      SourcePrepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Physicochemical Information
      ContaminantsFragment E: ≤1%
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 4 h at 20°C or for up to 8 h at 4°C or for up to 3 months at -70°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      341600-200UGCN 04055977195187

      Documentation

      Fibrinogen, Fragment D, Human Plasma (M)SDS

      タイトル

      英語版製品安全データシート((M)SDS) 

      Fibrinogen, Fragment D, Human Plasma 試験成績書(CoA)

      タイトルロット番号
      341600

      参考資料

      参考資料の概要
      Spraggon, G., et al. 1997. Nature 389, 455.
      Stirk, C.M., et al. 1993. Atherosclerosis 103, 159.
      Vogel, P., et al. 1993. Eur. Surg. Res. 25, 83.
      Azpiazu, I., and Chapman, D. 1992. Biochim. Biophys. Acta 1119, 268.
      Thompson, W.D., et al. 1992. J. Pathol. 168, 47.
      Fisher, E.G., et al. 1991. Haemostasis 21, 141.
      Ge, M., et al. 1991. Am. J. Physiol. 261, L283.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision24-June-2008 RFH
      DescriptionNative fibrinogen fragment D from human plasma prepared by plasmin digestion of purified fibrinogen followed by preparative electrophoresis. Thermolabile fragment. Complete proteolysis of a single fibrinogen molecule produces two D and one E fragments. Fragment D has been shown to increase endothelial monolayer permeability and to decrease polymorphonuclear leukocyte adhesion to endothelial cells. The D and E fragments have no common antigenic determinants; therefore, no cross-reactivity occurs.
      FormLyophilized
      FormulationLyophilized from 400 mM glycine, 150 mM NaCl.
      SourcePrepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Puritysingle band by SDS-PAGE
      ContaminantsFragment E: ≤1%
      SolubilitySterile distilled H₂O (200 µg/ml)
      Storage -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 4 h at 20°C or for up to 8 h at 4°C or for up to 3 months at -70°C.
      Toxicity Standard Handling
      ReferencesSpraggon, G., et al. 1997. Nature 389, 455.
      Stirk, C.M., et al. 1993. Atherosclerosis 103, 159.
      Vogel, P., et al. 1993. Eur. Surg. Res. 25, 83.
      Azpiazu, I., and Chapman, D. 1992. Biochim. Biophys. Acta 1119, 268.
      Thompson, W.D., et al. 1992. J. Pathol. 168, 47.
      Fisher, E.G., et al. 1991. Haemostasis 21, 141.
      Ge, M., et al. 1991. Am. J. Physiol. 261, L283.